Latest Headlines

Latest Headlines

EMA to again place HPV vaccines under its safety lens

While the European Medicines Agency said it "does not question that the benefits of HPV vaccines outweigh their risks," on Monday it announced a safety review of the shots that have thus far failed to live up to expectations partly due to safety concerns and a sex-related stigma.

Kite and bluebird join forces with some cutting-edge cancer tech

Immuno-oncology innovator Kite Pharma is joining gene therapy luminary bluebird bio to craft new treatments for HPV-related cancers, combining two high-profile technologies in hopes of developing targeted therapies.

Merck, Sanofi granted European Commission thumbs-up on Gardasil 9

Following behind a blockbuster is no easy task, but with a European Commission decision on Wednesday in favor of the vaccine, Merck's Gardasil 9 may just be up to the challenge of succeeding Gardasil.

One dose of GlaxoSmithKline's Cervarix may suffice

The recommended schedule for HPV vaccination is two or three doses, but some patients never make it back for all of the shots. This may cease to be a concern if future trials prove what scientists reported on Wednesday: A single dose of GlaxoSmithKline's Cervarix could work as well as the recommended two- or three-dose regimens at preventing the majority of cervical cancers.

Healthcare systems could benefit from covering HPV vaccine in boys, study says

A new analysis shows that healthcare systems can prevent throat cancer cases and save in long-term treatment costs by covering the HPV vaccine in young boys. Currently, Australia, Canada and the United States recommend the jab for boys, but only cover it for young girls.

Sanofi, Merck win EMA nod for Gardasil 9

Merck's new-and-improved Gardasil is making headway in Europe with the word late last week that the European Medicines Agency has recommended the jab against 9 types of human papillomavirus and will send its blessing to the European Commission.

Serum threatens Merck's Gardasil with low-cost competitor

Serum Institute of India, which has a history of undercutting its competition in the vaccine sphere, is expanding this undercutting game to HPV. Its low-cost competitor to Merck's Gardasil could hit the market in late 2018 at one-third the price.

Serum Institute of India poses challenge to Merck HPV vaccine

The Serum Institute of India, the world's fifth largest vaccinemaker by volume, is eyeing newer vaccines, including one for the human papillomavirus expected to be launched by late 2018 and sell at a third of the price of Merck & Co.'s blockbuster Gardasil, Bloomberg reported.

Merck Gardasil follow-up could block 90% of cervical cancers--if uptake improves, that is

Merck's investigational, 9-valent HPV vaccine has the potential to block about 90% of invasive cervical cancer cases worldwide, new research shows. But getting there will be no walk in the park. First, the company will have to solve some uptake problems that have been plaguing the candidate's predecessor, Gardasil, since it rolled out in 2006.

U.K. panel under pressure to extend use of Merck's Gardasil to boys

The debate around use of Merck's Gardasil in the United Kingdom is ratcheting up ahead of a meeting of the Joint Committee on Vaccinations and Immunisation (JCVI) in October.